-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The results of the phase 2 trial suggest that preoperative neoadjuvant immunotherapy not only kills tumors, but also microscopic cancer cells that were missed by surgery, which can lead to cancer recurrence or metastasis, the researchers said
"Ultimately, we think it's better for patients to have immunotherapy before surgery because people are healthier and their immune systems are in better shape to fight cancer before metastasis
Dr Marron added: "Typically, when cancer recurs, it is no longer a curable disease
Liver cancer is the most common type of liver cancer and the third leading cause of cancer-related death worldwide
The study's findings are important because so far, no treatment given to liver cancer patients shortly before or shortly after surgery has demonstrated any real improvement in survival
In late 2020, researchers gave 21 early-stage liver cancer patients two rounds of the immunotherapy drug cemiplimab, an anti-PD-1 antibody, before surgery
They found that in one-third of patients, their tumors died before surgery
This research enables the measurement of the immune system's response in a novel way
The TARGET platform shows how PD1 blockade increases the number of activated immune cells invading HCC tumors prior to surgery, inducing tumor necrosis and tumor shrinkage
"You don't usually study how drugs work in humans in such detail," Dr.
